VMP using weekly and subcutaneous bortezomib is well tolerated and efficacious for newly diagnosed and relapsed myeloma patients

被引：0
|
作者：
O'Sullivan, J. M. [1 ]
Kumar, S. [1 ]
Yeomans, C. [1 ]
Milner, G. [1 ]
Schey, S. [1 ]
Kazmi, M. [1 ]
Streetly, M. J. [1 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, Dept Haematol, London, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2014年 / 165卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
154
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [21] The Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients
    Takezako, Naoki
    Tokuhira, Michihide
    Sekiguchi, Naohiro
    Kurihara, Yuya
    Ito, Kenichi
    Kurimoto, Miwa
    Suzuki, Kenshi
    Kizaki, Masahiro
    BLOOD, 2016, 128 (22)
  • [22] Efficacy and Safety of Weekly Bortezomib Containing VMP Followed By Bortezomib Maintenance Therapy in Unfit or Frail Multiple Myeloma Patients
    Takezako, Naoki
    Tokuhira, Michihide
    Sekiguchi, Naohiro
    Kizaki, Masahiro
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E142 - E143
  • [23] Zonisamide monotherapy is well tolerated in patients with newly diagnosed epilepsy
    Rosenfeld, W. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 : 109 - 109
  • [24] Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
    Yimer, Habte
    Melear, Ason
    Faber, Edward
    Bensinger, William, I
    Burke, John M.
    Narang, Mohit
    Stevens, Don
    Gunawardena, Sriya
    Lutska, Yana
    Qi, Keqin
    Ukropec, Jon
    Qi, Ming
    Lin, Thomas S.
    Rifkin, Robert M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 (03) : 492 - 502
  • [25] A Prospective, Randomized, Phase III Study of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Versus Bortezomib, Melphalan and Prednisone (VMP) in Elderly Newly Diagnosed Myeloma Patients
    Palumbo, Antonio
    Bringhen, Sara
    Rossi, Davide
    Magarotto, Valeria
    Di Raimondo, Francesco
    Ria, Roberto
    Offidani, Massimo
    Nozzoli, Chiara
    Patriarca, Francesca
    Callea, Vincenzo
    Benevolo, Giulia
    Marasca, Roberto
    Guglielmelli, Tommasina
    Rizzo, Manuela
    Grasso, Mariella
    Petrucci, Maria Teresa
    Omede, Paola
    Gaidano, Gianluca
    Boccadoro, Mario
    BLOOD, 2008, 112 (11) : 243 - 243
  • [26] BORTEZOMIB, MELPHALAN, PREDNISONE AND THALIDOMIDE (VMPT) VERSUS BORTEZOMIB, MELPHALAN AND PREDNISONE (VMP) IN ELDERLY NEWLY DIAGNOSED MYELOMA PATIENTS: A PROSPECTIVE, RANDOMIZED, PHASE III STUDY
    Palumbo, A.
    Bringhen, S.
    Rossi, D.
    Ria, R.
    Berretta, S.
    Offidani, M.
    Patriarca, F.
    Nozzoli, C.
    Levi, A.
    Guglielmelli, T.
    Benevolo, G.
    Callea, V.
    Liberati, A. M.
    Crippa, C.
    Di Renzo, N.
    Catalano, L.
    De Sabbata, G.
    Rizzi, R.
    Feo, C.
    Mazza, R.
    Farina, G.
    Spadano, A.
    Pisani, F.
    Podda, L.
    Aitoro, G.
    Magarotto, V.
    Astolfi, M.
    Di Raimondo, F.
    Gaidano, G.
    Boccadoro, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 190 - 191
  • [27] Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma
    O'Gorman, Peter
    Laubach, Jacob P.
    O'Dwyer, Michael E.
    Krawczyk, Janusz
    Yee, Andrew J.
    Gilligan, Oonagh
    Cahill, Mary R.
    Rosenblatt, Jacalyn
    Quinn, John
    Murphy, Philip T.
    DiPietro, Heidi
    Perera, Meegahage Ratnakanthi
    Crotty, Gerard M.
    Cummings, Kristen
    Hayden, Patrick J.
    Browne, Paul
    Savell, Alexandra
    O'Leary, Hilary M.
    O'Keeffe, Denis
    Masone, Kelly
    Hennessy, Brian J.
    Garcia, Thomas Guerrero
    Scott, Kathleen
    Saeed, Khalid
    Bianchi, Giada
    Dowling, Paul
    Tierney, Ciara
    Richardson, Paul G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (05) : 562 - 573
  • [28] Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients (pts) with newly diagnosed multiple Myeloma.(MM): An effective and well-tolerated frontline regimen
    Berenson, James R.
    Yellin, Ori
    Woytowitz, Donald
    Flam, Marshall S.
    Cartmell, Alan
    Patel, Ravi
    Duvivier, Herb
    Nassir, Youram
    Swift, Regina A.
    BLOOD, 2007, 110 (11) : 1054A - 1054A
  • [29] Clinical Risk Factors for Peripheral Neuropathy in Patients Treated with Subcutaneous or Intravenous Bortezomib for Newly Diagnosed Multiple Myeloma
    Merz, Maximillan
    Salwender, Hans-Juergen
    Haenel, Mathias
    Bertsch, Uta
    Kunz, Christina
    Hielscher, Thomas
    Blau, Igor W.
    Scheid, Christof
    Mai, Elias Karl
    Hose, Dirk
    Schurich, Baerbel
    Munder, Markus
    Brossart, Peter
    Gerecke, Christian
    Lindemann, Hans Walter
    Zeis, Matthias
    Weisel, Katja C.
    Duerig, Jan
    Goldschmidt, Hartmut
    BLOOD, 2015, 126 (23)
  • [30] A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients
    Palumbo, A. P.
    Bringhen, S.
    Rossi, D.
    Berretta, S.
    Montefusco, V.
    Peccatori, J.
    Galli, M.
    Carella, A.
    Omede, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345